The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wiesmann, Frank, Vachta, Jan, Ehret, Robert, Walter, Hauke, Kaiser, Rolf, Stürmer, Martin, Tappe, André, Däumer, Martin, Berg, Thomas, Naeth, Gudrun, Braun, Patrick, Knechten, Heribert
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://ncbi.nlm.nih.gov/pubmed/21314993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-8-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados